Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Austedo
Overview
What is Austedo?
AUSTEDO (deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT2) inhibitor for oral administration. The molecular weight of deutetrabenazine is 323.46; the pKa is 6.31. Deutetrabenazine is a hexahydro-dimethoxybenzoquinolizine derivative and has the following chemical name: ()-1, 3, 4, 6, 7, 11b-hexahydro-9, 10-di(methoxy-d)-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-one.
The molecular formula for deutetrabenazine is CHDNO. Deutetrabenazine is a racemic mixture containing the following structures:
Deutetrabenazine is a white to slightly yellow crystalline powder that is sparingly soluble in water and soluble in ethanol.
AUSTEDO tablets contain 6 mg, 9 mg, or 12 mg deutetrabenazine, and the following inactive ingredients: ammonium hydroxide, black iron oxide, n-butyl alcohol, butylated hydroxyanisole, butylated hydroxytoluene, magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, polyethylene oxide, polysorbate 80, polyvinyl alcohol, povidone, propylene glycol, shellac, talc, titanium dioxide, and FD&C blue #2 lake. The 6 mg tablets also contain FD&C red #40 lake. The 12 mg tablets also contain FD&C yellow #6 lake.
What does Austedo look like?
What are the available doses of Austedo?
Tablets: 6 mg, 9 mg, and 12 mg ()
What should I talk to my health care provider before I take Austedo?
Pregnancy: Based on animal data, may cause fetal harm. ()
How should I use Austedo?
AUSTEDO® is indicated for the treatment of:
The dose of AUSTEDO is determined individually for each patient based on reduction of chorea or tardive dyskinesia and tolerability. When first prescribed to patients who are not being switched from tetrabenazine (a related VMAT2 inhibitor), the recommended starting dose of AUSTEDO is 6 mg administered orally once daily for patients with Huntington’s disease and 12 mg per day (6 mg twice daily) for patients with tardive dyskinesia.
What interacts with Austedo?
Sorry No Records found
What are the warnings of Austedo?
Sorry No Records found
What are the precautions of Austedo?
Sorry No Records found
What are the side effects of Austedo?
Sorry No records found
What should I look out for while using Austedo?
AUSTEDO is contraindicated in patients:
What might happen if I take too much Austedo?
Overdoses ranging from 100 mg to 1 g have been reported in the literature with tetrabenazine, a closely related VMAT2 inhibitor. The following adverse reactions occurred with overdosing: acute dystonia, oculogyric crisis, nausea and vomiting, sweating, sedation, hypotension, confusion, diarrhea, hallucinations, rubor, and tremor.
Treatment should consist of those general measures employed in the management of overdosage with any central nervous system-active drug. General supportive and symptomatic measures are recommended. Cardiac rhythm and vital signs should be monitored. In managing overdosage, the possibility of multiple drug involvement should always be considered. The physician should consider contacting a poison control center on the treatment of any overdose. Telephone numbers for certified poison control centers are listed on the American Association of Poison Control Centers website .
How should I store and handle Austedo?
Protect from light and moisture. [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP.Store the unit-dose blister packages in the carton until contents have been used.Protect from light and moisture. [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP.Store the unit-dose blister packages in the carton until contents have been used.Protect from light and moisture. [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP.Store the unit-dose blister packages in the carton until contents have been used.Dovonex (calcipotriene) Cream, 0.005% is available in:60 gram aluminum tubes NDC 50222-260-06120 gram aluminum tubes NDC 50222-260-12Dovonex (calcipotriene) Cream, 0.005% is available in:60 gram aluminum tubes NDC 50222-260-06120 gram aluminum tubes NDC 50222-260-12Dovonex (calcipotriene) Cream, 0.005% is available in:60 gram aluminum tubes NDC 50222-260-06120 gram aluminum tubes NDC 50222-260-12
